Targeting the Ubiquitin E1 as a Novel Anti-Cancer Strategy

E-ISSN： 1873-4286|19|18|3201-3209

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.18, 2013-06, pp. : 3201-3209

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy

Current Drug Targets, Vol. 11, Iss. 10, 2010-10 ,pp. : 1336-1340

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Phosphatidylserine in Anti-Cancer Therapy

Current Pharmaceutical Design, Vol. 15, Iss. 23, 2009-08 ,pp. : 2719-2723

Bentham Science Publishers

Access to resources Recommend Favorite

Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies

Current Cancer Drug Targets, Vol. 11, Iss. 3, 2011-03 ,pp. : 338-346

Bentham Science Publishers

Access to resources Recommend Favorite

NHE-1: A Promising Target for Novel Anti-cancer Therapeutics

Current Pharmaceutical Design, Vol. 18, Iss. 10, 2012-04 ,pp. : 1372-1382

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of Autophagy by Targeting ATG4B: Promises and Challenges of An Emerging Anti-cancer Strategy

Clinical Cancer Drugs, Vol. 2, Iss. 1, 2015-05 ,pp. : 61-70

Bentham Science Publishers

Access to resources Recommend Favorite